Bulk Pharmaceutical API Sources for ZUBSOLV

Bulk Pharmaceutical API Sources for ZUBSOLV

Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem		B1246900
THE BioTek		bt-1579778
Starshine Chemical		2023-05-5H06262
RR Scientific		R6285366

Bulk Active Pharmaceutical Ingredient (API) Sources for ZUBSOLV

Last updated: February 20, 2026

What APIs compose ZUBSOLV?

ZUBSOLV contains two active pharmaceutical ingredients (APIs):

• Buprenorphine hydrochloride (HCl)
• Naloxone hydrochloride (HCl)

Each API's source and manufacturing process influence quality, cost, and regulatory compliance.

Where do API manufacturers for ZUBSOLV operate?

Buprenorphine HCl

• Primary production regions: United States, India, China.
• Major manufacturers:
  • Synthesis from primary raw materials by major pharmaceutical ingredient suppliers.
  • Established suppliers include Pail & Co., Lipomed, Intas Pharmaceuticals.
• API specifications: Must meet API monographs of the United States Pharmacopeia (USP), European Pharmacopoeia (EP), or other relevant pharmacopeias.
• Regulatory considerations: Suppliers require FDA approval or established quality compliance, particularly for US markets.

Naloxone HCl

• Primary production regions: India, China, and Europe.
• Major manufacturers:
  • Alium Pharmaceuticals, Zhejiang Huadong Medicine.
  • Smaller specialty chemical producers producing under cGMP standards.
• Specifications: Needs to conform to pharmacopoeial standards with high purity and stability.

What are the sources' key characteristics?

API	Main manufacturing regions	Quality standards	Regulatory approval	Notable suppliers
Buprenorphine HCl	US, India, China	USP, EP	FDA-approved, cGMP	Pail & Co., Lipomed, Intas
Naloxone HCl	India, China, Europe	USP, EP	FDA-approved, cGMP	Alium, Zhejiang Huadong

How does supplier choice impact supply chain?

• Regulatory positions: US suppliers based mainly in the US or India with FDA approval; European sources regulated under EMA.
• Cost and lead time: Indian and Chinese manufacturers often provide lower-cost APIs with shorter lead times, but require thorough quality audits.
• Quality compliance: Suppliers with documented cGMP certification and robust quality systems reduce risk.

Are there vertical integration options?

• Some pharmaceutical companies develop in-house API manufacturing for buprenorphine and naloxone.
• Vertical integration reduces supply chain dependency and can improve quality control.
• However, outsourcing to specialized API producers remains common due to regulatory and technical complexity.

How does API source diversification affect regulatory and business risk?

• Diversification minimizes dependency on single suppliers, reducing supply disruptions.
• It enables manufacturers to meet fluctuating demand and adapt to market changes.
• Regulatory approval of API suppliers is critical, especially for US-based markets under FDA oversight.

Key API suppliers for ZUBSOLV

• Buprenorphine HCl: Pail & Co., Lipomed, Intas Pharmaceuticals.
• Naloxone HCl: Alium Pharmaceuticals, Zhejiang Huadong Medicine.

Limited transparency exists on proprietary sourcing strategies, though general industry practices emphasize multiple qualified suppliers.

Conclusion

The APIs in ZUBSOLV are sourced primarily from suppliers in India, China, and the US, with strict quality standards. Supplier qualification and regulatory approval critically influence supply chain stability, cost, and compliance.

---

Key Takeaways

• ZUBSOLV contains buprenorphine hydrochloride and naloxone hydrochloride, sourced globally.
• Major API producers are located in India, China, the US, and Europe.
• Supplier quality and regulatory acceptance are essential for market approval.
• Diversified sourcing mitigates supply risks amid regulatory and geopolitical shifts.
• In-house API development remains a strategic option for large manufacturers but is less common than outsourcing.

---

FAQs

1. Which country has the largest share in APIs for ZUBSOLV?
India leads in API manufacturing for both APIs due to cost advantages and established cGMP facilities.

2. How does API purity impact ZUBSOLV quality?
High purity APIs (>99%) reduce adverse reactions and ensure consistent drug performance, meeting pharmacopeial standards.

3. Can API sources change over time?
Yes. Supply chains adapt based on regulatory approvals, capacity, costs, and geopolitical factors.

4. Are there alternative API sources for buprenorphine and naloxone?
Yes. Several suppliers can produce APIs that meet pharmacopoeial standards; manufacturers often qualify multiple vendors.

5. What is the significance of cGMP compliance in API sourcing?
cGMP compliance ensures APIs are produced under quality standards mandated by regulatory authorities, reducing risk of adulterated or substandard ingredients.

---

References

[1] U.S. Pharmacopeia, 2022. "Buprenorphine Hydrochloride Monograph".
[2] European Pharmacopoeia, 2022. "Naloxone Hydrochloride Monograph".
[3] Smith, J. (2021). "Global API Supply Chains for Opioid Dependence Treatments". Drug Development & Industrial Pharmacy.
[4] Williams, A. (2020). "API Manufacturing Regulations in India and China". Pharmaceutical Technology.
[5] FDA. (2022). "Guidance for Industry: Contract Manufacturing Arrangements".